Claris collects $118M to take eye drop into pivotal testing next yearnews2026-07-28T12:00:02+00:00July 28th, 2026|Endpoints News|
GSK to start three-year plan to save cash, takes £1.33B hit on cough trial failurenews2026-07-28T11:35:41+00:00July 28th, 2026|Endpoints News|
Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholismnews2026-07-28T11:00:10+00:00July 28th, 2026|Endpoints News|
Virginia federal judge says FDA should reconsider mifepristone restrictionsnews2026-07-27T18:39:32+00:00July 27th, 2026|Endpoints News|
The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO saysnews2026-07-27T18:30:58+00:00July 27th, 2026|Endpoints News|
Capricor’s DMD therapy lacks efficacy, FDA says ahead of adcommnews2026-07-27T17:40:36+00:00July 27th, 2026|Endpoints News|
Six wellness peptides win backing from FDA advisory committeenews2026-07-27T17:21:05+00:00July 27th, 2026|Endpoints News|
Yarrow to begin trading as it targets Graves; FDA approves Otsuka’s ADHD pillnews2026-07-27T15:40:29+00:00July 27th, 2026|Endpoints News|
MapLight’s schizophrenia drug dampens once-daily hopes despite Phase 2 winnews2026-07-27T15:17:42+00:00July 27th, 2026|Endpoints News|
Legend CEO Ying Huang resigns; Carvykti chief named interim leadernews2026-07-27T13:38:43+00:00July 27th, 2026|Endpoints News|
